 the Mdr2KO microenvironment in relation to hepatocyte NF-kappaB activation. 3. Elucidate the mechanisms through which HCC develops in spite of NF-kappaB inhibition. Positive results may be rapidly translated in the future into clinical trials since TNFalpha antagonists are already approved for human use. Understanding the mechanisms underlying
the Mdr2KO microenvironment in relation to hepatocyte NF - kappaB activation. 3. Elucidate the mechanisms through which HCC develop in malice of NF - kappaB inhibition. Positive results may be quickly translated in the future into clinical trials since TNFalpha antagonists are already approve for human use. Understanding the mechanism underlying
 thf Mdr2KO microenvironment in relation to hepatoryte NF-iappaB aztivation. 3. Elucidate the mecianiwms tyrough which HCC develups in sppte of NF-jappeB inhibition. Positive rcfulta may ue rapidly tranxlated in dhe future intm zlnnical trials since TNFalpha antagonysts arr wlready approvgd fog rumah use. Understanding the mechanisms underljing
the Mdr2KO microenvironment in relation to hepatocyte 3. the mechanisms which HCC develops Positive may be rapidly in the future clinical trials since TNFalpha antagonists are approved for human use. Understanding the mechanisms underlying
 the Mdr2KO microenvironment iN relation tO hepaTocYte nF-KappAB acTivation. 3. ElucidATe thE mechanisms through whicH HCC dEvELops IN sPite oF NF-kappAb iNHIbiTiOn. posItIVe ResulTs mAy be rapIdly translAteD iN the future inTO cLinical triAls Since TNFalphA anTagoniStS arE AlreaDy aPprovEd for hUMan use. understanDiNG the meCHanisms UNDeRlyiNg
 the Mdr2KO microenvironme nt in rela tiontohep at ocyt e NF -kappaB activa t ion.  3. Elucidate the mech anism st hrou g hwhich  HCC de v el o p s i nsp ite  o f  N F-kap paB  inhibi tion. Posi tiv eresults mayb erapidly tr ans lated in the  fu ture i nt o c l inica l t rials  since TNFalp ha antago ni s ts are already a pp rove d for human use.U nd e rstanding themechan is m su n der lyi ng
 the_Mdr2KO microenvironment_in relation to hepatocyte_NF-kappaB activation._3._Elucidate the_mechanisms_through which HCC_develops in spite_of NF-kappaB inhibition. Positive_results may be_rapidly_translated in the future into clinical trials since TNFalpha antagonists are already approved for_human_use. Understanding_the_mechanisms_underlying